STARLITE 1: Phase 1b/2 Study of Combined ¹⁷⁷Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-naïve Patients with Advanced Clear-cell Renal Cell Carcinoma.

IF 4.8 2区医学 Q1 UROLOGY & NEPHROLOGY

European urology focus Pub Date : 2025-04-26 DOI:10.1016/j.euf.2025.04.003

Elshad Hasanov, Lesley Flynt, Rebecca Slack Tidwell, Hyunsoo Hwang, Roserika Brooks, Lauren Michelle Wood, Travis Solley, Mashaal Syed, Aradhana M Venkatesan, Eric Jonasch

引用次数: 0

Abstract

This trial is evaluating the combination of ¹⁷⁷Lu-girentuximab with nivolumab and cabozantinib to enhance the complete response rate in advanced clear-cell renal cell carcinoma (ccRCC). The aim is to activate cGAS-STING-induced antitumor immunity via targeted radioimmunotherapy damage to DNA. If successful, this approach could establish a novel paradigm that combines radiopharmaceuticals with immunotherapy and targeted therapy in ccRCC.

查看原文本刊更多论文

STARLITE 1: 177Lu-Girentuximab联合Cabozantinib和Nivolumab治疗Treatment-naïve晚期透明细胞肾细胞癌患者的1b/2期研究

该试验正在评估177Lu-girentuximab与nivolumab和cabozantinib联合使用以提高晚期透明细胞肾细胞癌（ccRCC）的完全缓解率。目的是通过靶向放射免疫治疗损伤DNA来激活cgas - sting诱导的抗肿瘤免疫。如果成功，这种方法可以建立一种新的范例，将放射性药物与免疫治疗和靶向治疗结合起来治疗ccRCC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology focus Medicine-Urology

CiteScore

10.40

自引率

3.70%

发文量

274

审稿时长

23 days

期刊介绍： European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU). EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.

STARLITE 1: Phase 1b/2 Study of Combined 177Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-naïve Patients with Advanced Clear-cell Renal Cell Carcinoma.

Abstract

STARLITE 1: Phase 1b/2 Study of Combined ¹⁷⁷Lu-Girentuximab plus Cabozantinib and Nivolumab in Treatment-naïve Patients with Advanced Clear-cell Renal Cell Carcinoma.